Chinese Journal of Dermatology ›› 2020, Vol. 53 ›› Issue (6): 487-489.doi: 10.35541/cjd.20190185
• Reviews • Previous Articles
Wang Yuan, Feng Suying
Received:
2019-01-02
Revised:
2019-07-04
Online:
2020-06-15
Published:
2020-06-01
Contact:
Feng Suying
E-mail:fengsuying@medmail.com.cn
Supported by:
Wang Yuan, Feng Suying. Drug-induced bullous pemphigoid[J]. Chinese Journal of Dermatology, 2020, 53(6): 487-489.doi:10.35541/cjd.20190185
[1] | Stavropoulos PG, Soura E, Antoniou C. Drug⁃induced pemphigoid: a review of the literature[J]. J Eur Acad Dermatol Venereol, 2014,28(9):1133⁃1140. doi: 10.1111/jdv.12366. |
[2] | Lee JJ, Downham TF 2nd. Furosemide⁃induced bullous pemphigoid: case report and review of literature[J]. J Drugs Dermatol, 2006,5(6):562⁃564. |
[3] | Bean SF, Good RA, Windhorst DB. Bullous pemphigoid in an 11⁃year⁃old boy[J]. Arch Dermatol, 1970,102(2):205⁃208. |
[4] | Neri I, Greco A, Bassi A, et al. Bullous pemphigoid in infant post vaccination: myth or reality?[J]. Int J Immunopathol Pharmacol, 2016,29(2):295⁃299. doi: 10.1177/0394632015603796. |
[5] | Cortés⁃Pinto C, Baradad Brusau M, Vilardell Vilellas F, et al. Bullous pemphigoid in a 3⁃month⁃old infant after vaccination[J]. Clin Exp Dermatol, 2019,44(3):341⁃343. doi: 10.1111/ced.13752. |
[6] | Baroero L, Coppo P, Bertolino L, et al. Three case reports of post immunization and post viral bullous pemphigoid: looking for the right trigger[J]. BMC Pediatr, 2017,17(1):60. doi: 10.1186/s12887⁃017⁃0813⁃0. |
[7] | Walmsley N, Hampton P. Bullous pemphigoid triggered by swine flu vaccination: case report and review of vaccine triggered pemphigoid[J]. J Dermatol Case Rep, 2011,5(4):74⁃76. doi: 10. 3315/jdcr.2011.1081. |
[8] | Kawaguchi Y, Shimauchi R, Nishibori N, et al. Dipeptidyl peptidase⁃4 inhibitors⁃associated bullous pemphigoid: a retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients[J]. J Diabetes Investig, 2019,10(2):392⁃398. doi: 10.1111/jdi.12877. |
[9] | Béné J, Moulis G, Bennani I, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case⁃noncase study in the French Pharmacovigilance Database[J]. Br J Dermatol, 2016,175(2):296⁃301. doi: 10.1111/bjd.14601. |
[10] | Izumi K, Nishie W, Mai Y, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid[J]. J Invest Dermatol, 2016,136(11):2201⁃2210. doi: 10.1016/j.jid.2016.06.622. |
[11] | Chijiwa C, Takeoka S, Kamata M, et al. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase⁃4 inhibitor⁃related bullous pemphigoid[J]. J Dermatol, 2018,45(5):596⁃599. doi: 10.1111/1346⁃8138.14245. |
[12] | García⁃Díez I, Ivars⁃Lleó M, López⁃Aventín D, et al. Bullous pemphigoid induced by dipeptidyl peptidase⁃4 inhibitors. Eight cases with clinical and immunological characterization[J]. Int J Dermatol, 2018,57(7):810⁃816. doi: 10.1111/ijd.14005. |
[13] | Skandalis K, Spirova M, Gaitanis G, et al. Drug⁃induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase⁃IV inhibitors plus metformin[J]. J Eur Acad Dermatol Venereol, 2012,26(2):249⁃253. doi: 10.1111/j.1468⁃3083.2011. 04062.x. |
[14] | Ameglio F, D′Auria L, Bonifati C, et al. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity[J]. Br J Dermatol, 1998,138(4):611⁃614. doi: 10.1046/j.1365⁃2133.1998.02169.x. |
[15] | Nin M, Tokunaga D, Ishii N, et al. Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept[J]. J Dermatol, 2013,40(1):55⁃56. doi: 10.1111/j.1346⁃8138.2012. 01659.x. |
[16] | Ricci M, Zauli S, Zelante A, et al. Bullous pemphigoid occurring under anti⁃tumor necrosis factor⁃α therapy[J]. Int J Colorectal Dis, 2014,29(12):1573⁃1574. doi: 10.1007/s00384⁃014⁃1924⁃9. |
[17] | Boussemart L, Jacobelli S, Batteux F, et al. Autoimmune bullous skin diseases occurring under anti⁃tumor necrosis factor therapy: two case reports[J]. Dermatology, 2010,221(3):201⁃205. doi: 10. 1159/000318008. |
[18] | Kluk J, Goulding JM, Bhat J, et al. Drug⁃induced bullous pemphigoid: cases triggered by intravenous iodine and etanercept[J]. Clin Exp Dermatol, 2011,36(8):871⁃873. doi: 10.1111/j. 1365⁃2230.2011.04102.x. |
[19] | Monnier⁃Murina K, Du Thanh A, Merlet⁃Albran S, et al. Bullous pemphigoid occurring during efalizumab treatment for psoriasis: a paradoxical auto⁃immune reaction?[J]. Dermatology, 2009,219(1):89⁃90. doi: 10.1159/000207792. |
[20] | Bordignon M, Belloni⁃Fortina A, Pigozzi B, et al. Bullous pemphigoid during long⁃term TNF⁃alpha blocker therapy[J]. Dermatology, 2009,219(4):357⁃358. doi: 10.1159/000243805. |
[21] | Liu LY, Bates ME, Jarjour NN, et al. Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF⁃alpha[J]. J Immunol, 2007,179(7):4840⁃4848. doi: 10. 4049/jimmunol.179.7.4840. |
[22] | Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy[J]. Am J Clin Dermatol, 2018,19(3):345⁃361. doi: 10.1007/s40257⁃017⁃0336⁃3. |
[23] | Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti⁃PD⁃1 and anti⁃PD⁃L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy[J]. J Am Acad Dermatol, 2018,79(6):1081⁃1088. doi: 10.1016/j.jaad. 2018.07.008. |
[24] | Lopez AT, Khanna T, Antonov N, et al. A review of bullous pemphigoid associated with PD⁃1 and PD⁃L1 inhibitors[J]. Int J Dermatol, 2018,57(6):664⁃669. doi: 10.1111/ijd.13984. |
[25] | Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD⁃1 and PD⁃L1[J]. Cancer Immunol Res, 2016,4(5):383⁃389. doi: 10.1158/2326⁃6066.CIR⁃15⁃0123. |
[1] | Xia Lingyin, Lu Qin, Wang Xiaosu, Huang Meirong, Min Xun, Huang Jian. Expression and purification of a peptide fragment of 660 - 1468 amino acids in Neisseria gonorrhoeae NGO2105 protein as well as preparation and identification of its polyclonal antibody [J]. Chinese Journal of Dermatology, 2023, 56(3): 216-221. |
[2] | Wang Nannan, Cai Tingting, Liu Xia, Zhu Wanping. A comparative study on rat models of psoriasis-like lesions induced by different cytokines combined with imiquimod [J]. Chinese Journal of Dermatology, 2023, 56(12): 1146-1153. |
[3] | Shanghai Society of Dermatology and Venereology, Shanghai Society of Target Molecular Oncology, Shanghai Medical Association. Consensus on the management of cutaneous adverse reactions to anti-tumor drugs [J]. Chinese Journal of Dermatology, 2023, 56(10): 907-919. |
[4] | Hu Yu, Gu Heng, Chen Kun. Disease burden and unmet medical needs in Chinese patients with moderate-to-severe psoriasis: a systematic review [J]. Chinese Journal of Dermatology, 2023, 56(10): 965-972. |
[5] | Yang Ying, Guo Qing, Hou Suchun, Min Xue, Tian Jiabin, Qiao Zhuhui, Lin Jialin, Wang Xiaofei, Wu Lantuya, Zhang Zhenying, Li Zhengfeng, Wang Bin, Liu Xiaoming. COVID-19 vaccination status and its impact on psoriatic lesions in patients with psoriasis treated with biologics: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2023, 56(1): 59-63. |
[6] | Zhou Xue, Yu Zengyang, Chen Youdong, Guo Chunyuan, Yu Qian, Hu Yifan, Yao Lingling, Shi Yuling, . Tumor necrosis factor α-mediated low expression of fatty acid desaturase 2 in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 752-758. |
[7] | Yao Lingling, Yu Zengyang, Guo Chunyuan, Zhou Jing, Cui Lian, Yu Qian, Yu Yingyuan, Zhou Xue, Cai Jiangluyi, Shi Yuling, . Changes in circadian gene cryptochrome 2 expression in mouse models of psoriasis and HaCaT cells and their underlying mechanisms [J]. Chinese Journal of Dermatology, 2022, 55(9): 759-766. |
[8] | Sun Jie, Wang Rui, Li Chengxin. Tumor necrosis factor-α inhibitor?induced psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 821-824. |
[9] | Gao Zirui, Zhao Pei, Dou Yuanqing, Liu Ping, Zhang Jianzhong. Efficacy and safety of dupilumab in the treatment of adult prurigo nodularis [J]. Chinese Journal of Dermatology, 2022, 55(7): 562-565. |
[10] | Huang Xin, Chen Xiaoyun, Li Yaping, Liang Xingkun, Zhang Guiying, Zhou Ying, Zhan Yi, Luo Shuaihantian, Liao Jieyue, Xiao Rong, Long Hai. Efficacy and safety of dupilumab in the treatment of 123 cases of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(6): 486-493. |
[11] | Liu Bo, Song Xiaoting, Li Ruoyu, Zhao Zuotao. Clinical efficacy and safety of dupilumab in the treatment of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 295-298. |
[12] | Wang Yue, Yan Yulin. Analysis of adverse drug reactions and reasons for drug discontinuation during acitretin therapy in 171 patients with psoriasis vulgaris [J]. Chinese Journal of Dermatology, 2022, 55(3): 242-245. |
[13] | Li Hao, Wang Li, Han Xianwei, Sun Tong, Su Fang, Sun Xiaodong, Han Ying, Yang Guoling, Liu Xiaoming, Wang Kaibo. Analysis of clinical characteristics of bullous pemphigoid developing after the treatment with dipeptidyl peptidase-Ⅳ inhibitors in 32 patients with diabetes mellitus [J]. Chinese Journal of Dermatology, 2022, 55(3): 213-218. |
[14] | Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275. |
[15] | Zou Meirong, Wang Sheng. Cutaneous immune-related adverse reactions induced by immune checkpoint inhibitors [J]. Chinese Journal of Dermatology, 2022, 55(11): 1026-1030. |
|